Clinical Trial Update: Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating post-transplant cyclophosphamide, bortezomib, and abatacept to prevent graft-versus-host disease is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Abatacept (abatacept)
• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Northwell Health | Conditions: Graft-versus-host Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING